

To Our Shareholders



I thank you sincerely for your ongoing support. Here, we provide an overview of the Company's operating performance during the first quarter of the fiscal year ending March 31, 2011.

Haruo Naito

Haruo Naito
Director, President and CEO
(Representative Executive Officer)



Overview of Consolidated Financial Results

- ◆ Net sales totaled ¥204,463 million (up 5.0% year on year).
- ◆ Sales of *Aricept*, an anti-Alzheimer's agent, increased to ¥82,928 million (up 10.9% year on year). Sales of *Pariet* (U.S. brand name: *Aciphex*), a proton pump inhibitor, came to ¥35,284 million (down 3.9% year on year). Sales of oncology related products came to ¥20,304 million (up 2.9% year on year).
- ◆ Operating income, ordinary income and net income all exceeded results recorded in the same period of the previous fiscal year, driven by increased gross profit as a result of higher sales as well as improved efficiencies in selling, general and administrative expenses.

Consolidated Financial Results

(Figures are rounded.)

Full year Three months ended June 30



This report includes forward-looking statements with respect to plans and forecasts of future results. Please understand that actual performance may differ significantly from these projections.

Ongoing Research & Development Projects

Development progress from April 2010 onwards were as follows.

Therapeutic Areas	Product Name (Research Code)	Description	Region	Phase II	Phase III	Submission	Approved	Form
Oncology and Supportive Care	MORAb-003	Anticancer agent/Ovarian cancer	Japan					Injection
	ONTAK (E7272)	Additional indications: Melanoma	U.S.					Injection
	E7080	Anticancer agent/Melanoma	U.S.					Oral
Neurology	Aricept (E2020)	Additional dosage & administration, formulation: Higher dose <i>Aricept 23mg tablet</i> was approved.	U.S.				July	Oral
	BANZEL (E2080)	Additional Formulation: Oral suspension	U.S.					Oral
		Anti-epileptic agent/ Adjunctive therapy for LGS	Japan					Oral
Vascular and Immunological Reaction	Tambocor	Additional indication, dosage & administration: Tachyarrhythmia in pediatric patients	Japan				May	Oral
Gastrointestinal Disorders	Pariet/ AcipHex (E3810)	Additional indication, dosage & administration: Non-erosive gastroesophageal reflux disease (GERD)	Japan				June	Oral
		Additional indications: Concomitant therapy for eradication of <i>Helicobacter pylori</i>	Japan				June	Oral
		Additional dosage & administration: Reflux esophagitis	Japan					Oral
		Additional Formulation: <i>Aciphex extended-release 50mg formulation</i> was approved.	U.S.					Oral

Topics

Higher Dose *Aricept 23mg Tablet*

In July 2010, this dosage was approved in the United States. The *Aricept 23mg Tablet* offers another dosing option for patients with moderate-to-severe Alzheimer's disease.

Anticancer Agent *Eribulin Mesylate (E7389)*

In May 2010, *Eribulin Mesylate* was granted priority review status by the Japanese Ministry of Health, Labour and Welfare and the U.S. Food and Drug Administration. Through this agent, Eisai aims to address the unmet medical needs of breast cancer patients as well as healthcare professionals as quickly as possible.

New Parenteral Oncology Drug Production Facility

A new parenteral oncology drug production facility opened at Eisai's U.S. plant in North Carolina in May 2010. For Eisai, the new facility will serve as an important global production site for anticancer agents, including *Eribulin Mesylate*, upon its approval.



Postherpetic Neuralgia Treatment *Lyrica Capsules*

In June 2010, *Lyrica Capsules* launched in Japan. This treatment, developed by Pfizer Inc., has a mechanism of action that is new among analgesic treatments. Pfizer Japan and Eisai are jointly promoting sale of the drug.

